Solid IO, a medtech startup, closed its first funding round of €800,000 to develop a tumor-on-chip platform that accurately simulates patient-specific cancer responses. This innovative technology aims to improve patient outcomes in cancer treatment while reducing unnecessary side effects.

At Solid IO, we are transforming oncology and immunotherapy with organ-on-chip technology. Our patient-specific tumor models provide real-time, biologically relevant data, empowering oncologists, researchers, and pharmaceutical innovators to make precise, informed treatment decisions.
By replicating the tumor microenvironment, our platform eliminates uncertainty, accelerating drug development, optimizing clinical trials, and expanding access to advanced cancer therapies.

https://www.solid-io.com/

Therapeutics

Medical

Solid IO raised €800K in its first funding round to enhance cancer treatment with tumor-on-chip technology.

Description

Company Information

Related People

Funding Insights

Solid IO raised €800K in its first funding round to enhance cancer treatment with tumor-on-chip technology.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information